Effect of Treatement with Omega-3 Fattyacids and Atorvastatin in Patients with Combined Dyslipidemia

Abstract

Objective: Treatment with omega-3 free fatty acids determines a significant reduction of the serum level of triglycerides, reduces the risk of coronary artery disease-related death, and nonfatal cardiac events, and suppresses cardiac arrhythmias. We evaluate the effectiveness of omega-3 free fatty acids added to atorvastatin in patients with combined dyslipidemia. Material and method: We evaluate 40 patients, 20 males (50%), aged between 35 and 55 years old, nonsmokers, nonhypertensive, and with no diagnosed coronary artery disease, randomized in Group A (20p.) treated 8 weeks with atorvastatin 20mg/day and Group B (20p.) Treated free fatty acids 3Gr/day last 4 weeks added to atorvastatin 20mg/day 8 weeks. Statistical analysis pair t-Student test. Results: Adding omega-3 fatty acids 3gr/day to the treatment with atorvastatin significantly reduce the plasmatic level of total cholesterol( 280mg/dl vs 256mg/dl, p < 0,003), triglycerides (180 vs 170 mg/dl, p <0,01), and non-HDL Cholesterol (-4% Vs 1,5%, P <0,004). Conclusions: combining the atorvastatin treatment with omega-3 free fatty acids in patients with combined dyslipidemia, causes an important decrease in plasma triglycerides, and to a lesser degree LDL and total cholesterol.